Oral Tranexamic Acid for the Treatment of Melasma: A Review
- 1 June 2018
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Dermatologic Surgery
- Vol. 44 (6), 814-825
- https://doi.org/10.1097/dss.0000000000001518
Abstract
Melasma is a common acquired disorder of hyperpigmentation that commonly affects those with skin of color. Tranexamic acid (TXA) is a novel treatment for melasma that has a multimodal mechanism of action. To provide a comprehensive review of the literature regarding the evidence on the mode of action, safety profile, and efficacy of TXA in the treatment of melasma. The literature was searched for publications on TXA in the treatment of melasma using MEDLINE, Scopus, and Google Scholar. Oral TXA has clearly demonstrated the efficacy for melasma in Asian skin, even in low doses (e.g., 500 mg daily) over short periods (8–12 weeks). It is also a safe therapeutic option, which is easy to administer with few and mild side effects. Studies have shown that TXA does not increase the thromboembolic risk, although patients should be screened carefully for contraindications and risk factors prior to commencement of the therapy. Oral TXA is a safe and efficacious treatment for refractory melasma. It should be considered in cases that are unresponsive to topical hydroquinone and combination topical therapy over a period of approximately 12 weeks and without contraindications to oral TXA.Keywords
This publication has 56 references indexed in Scilit:
- Treatment of melasma with oral administration of compound tranexamic acid: a preliminary clinical trialJournal of the European Academy of Dermatology and Venereology, 2013
- Plasmin Inhibitors Prevent Leukocyte Accumulation and Remodeling Events in the Postischemic MicrovasculaturePLOS ONE, 2011
- Impact of Long-Wavelength UVA and Visible Light on Melanocompetent SkinJournal of Investigative Dermatology, 2010
- Mechanism of the Inhibitory Effect of Tranexamic Acid on Melanogenesis in Cultured Human Melanocytes in the Presence of Keratinocyte-conditioned MediumJournal of Health Science, 2007
- Linear hyperpigmentation with extensive epidermal apoptosis: a variant of linear lichen planus pigmentosus?Journal of the American Academy of Dermatology, 2004
- A double-blind, comparative, placebo-controlled study of the efficacy and tolerability of 4% hydroquinone as a depigmenting agent in melasmaJournal of Dermatological Treatment, 2000
- Tranexamic AcidDrugs, 1999
- Analysis of the Mechanism of Ultraviolet (UV) B Radiation – Induced Prostaglandin E2 Synthesis by Human Epidermoid Carcinoma CellsJournal of Investigative Dermatology, 1993
- After antifibrinolytic therapyAnnals of Emergency Medicine, 1989
- Stimulatory Effect of Prostaglandin E2 on the Configuration of Normal Human Melanocytes In VitroJournal of Investigative Dermatology, 1987